VALNEVA

Research VALNEVA (AYJ) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• TickerAYJ
• ExchangeMU
• CountryFrance
• CurrencyEUR
• Financial periodFY2025
• RevenueEUR 174.66M
• Revenue growth3.0%
• Net income-EUR 115.19M
• Free cash flow-EUR 57.31M
• Gross margin38.7%

About VALNEVA

Note 1 General Information 1.1 Company Information Valneva SE (the Company) and its subsidiaries (the Group or Valneva) is a group specialized in the development and commercialization of prophylactic vaccines against infectious diseases for which medical needs are not met. The Company adopts a highly specialized and targeted approach, using its expertise in different vaccination methods to develop vaccines for diseases for which no vaccines exist or where existing solutions can be improved.

Frequently asked questions

What does VALNEVA do?

Note 1 General Information 1.1 Company Information Valneva SE (the Company) and its subsidiaries (the Group or Valneva) is a group specialized in the development and commercialization of prophylactic vaccines against infectious diseases for which medical needs are not met.